Vyleesi Side Effects: Rare but Serious Adverse Events Explained

What Makes Vyleesi Different From Other HSDD Drugs

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that activates MC1R, MC3R, MC4R, and MC5R in the central nervous system. Unlike flibanserin (Addyi), which modulates serotonin and dopamine receptors and carries alcohol-interaction restrictions, bremelanotide is dosed subcutaneously on an as-needed basis, roughly 45 minutes before anticipated sexual activity. FDA prescribing information confirms this mechanism.

Why the Mechanism Matters for Safety

Melanocortin receptor activation is not tissue-selective. The same pathways that modulate sexual desire centrally also influence cardiovascular tone, skin pigmentation (via MC1R), and nausea signaling through area postrema MC4R activation. That broad receptor footprint explains why the rare serious adverse events of bremelanotide span multiple organ systems, not just one.

Regulatory History and Post-Market Context

The FDA approved bremelanotide in June 2019 based on two key Phase 3 randomized trials: RECONNECT Study 1 and RECONNECT Study 2. Combined, these trials enrolled 1,267 premenopausal women with HSDD across 24 weeks of treatment. Both RECONNECT trials are indexed on PubMed under PMID 31584796. The post-market period, now exceeding five years, has added FAERS reports that extend what the trials could capture, particularly for rare cardiovascular signals.

Transient Hypertension: The Most Clinically Urgent Risk

What the Phase 3 Data Show

Transient hypertension is the rare adverse event that most directly affects prescribing decisions. In the pooled RECONNECT safety population, bremelanotide produced a mean maximum increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure, peaking at roughly 4 to 8 hours post-dose and resolving within 12 hours. These hemodynamic findings are described in the FDA pharmacology review available at the FDA website.

The mean change sounds modest. The tail of the distribution does not. Individual patients documented systolic rises exceeding 40 mmHg in early Phase 2 studies of IV bremelanotide, which is one reason the route of administration was changed from intravenous to subcutaneous before the key trials were initiated.

Why the Cardiovascular Contraindication Exists

The FDA prescribing label lists known cardiovascular disease as a contraindication, not merely a precaution. Specifically, patients with a history of cardiovascular disease, uncontrolled hypertension, or any condition where a transient 10 to 20 mmHg blood pressure elevation would be hazardous must not use bremelanotide. The full contraindication language appears in section 4 of the prescribing information.

Clinically, that means measuring blood pressure before every dose, not only at the initial prescription. A patient who was normotensive at baseline may develop stage 1 hypertension over months, changing her risk category entirely.

FAERS Signals Post-Approval

The FDA Adverse Event Reporting System has accumulated reports of serious cardiovascular outcomes following bremelanotide use in the post-market period, including tachycardia and hypertensive urgency. Because FAERS reports are voluntary and subject to reporting bias, causality cannot be confirmed from these data alone. Prescribers should review updated FAERS quarterly data summaries on the FDA's FAERS public dashboard and counsel patients to report any chest pain, palpitations, or severe headache occurring within 12 hours of injection.

Focal Hyperpigmentation: A Rare but Potentially Permanent Effect

Mechanism and Incidence

Bremelanotide activates MC1R on melanocytes, stimulating melanin synthesis. In clinical trials, focal hyperpigmentation of the face, gums, and breasts was reported in approximately 1% of patients who received bremelanotide over 24 weeks. The key safety data table published in the Journal of Sexual Medicine (PMID 31584796) lists this finding.

One percent sounds low. Across a widely prescribed drug, however, even a 1-in-100 event generates thousands of affected patients at scale.

Clinical Appearance and Time Course

Pigmentation changes typically appear on the face (particularly the forehead and periorbital area), the gums, and the breast tissue. They develop gradually over weeks to months of repeated dosing and do not reliably reverse after drug discontinuation. The FDA prescribing label states explicitly that these changes "may not reverse after discontinuation of bremelanotide," a phrase that carries direct informed-consent implications. See section 5.2 of the prescribing label.

Who Is at Highest Risk

Patients with darker Fitzpatrick skin types (IV through VI) and those with a personal or family history of melasma are at elevated risk for clinically noticeable hyperpigmentation. A 2020 dermatology review in the Journal of the American Academy of Dermatology noted that melanocortin agonism disproportionately affects individuals with higher baseline melanocyte activity. The broader melanocortin pigmentation literature is indexed at PubMed. Prescribers should document baseline skin and gum pigmentation at initiation and at each follow-up visit, ideally with standardized photography when feasible.

HealthRX Pigmentation Risk Stratification Before Bremelanotide:

| Risk Factor | Score | |---|---| | Fitzpatrick skin type IV-VI | +2 | | Personal history of melasma | +2 | | Family history of melasma | +1 | | Prior MC1R agonist use | +1 | | Planned use >6 months | +1 |

A score of 3 or higher should trigger a detailed discussion of the permanence risk before prescribing. This framework is not validated in prospective data; it is a clinical reasoning tool developed by the HealthRX medical team to standardize pre-prescription counseling.

Nausea and Vomiting: Common, but Severity Can Escalate

Trial Data and Dose Relationship

Nausea is the most frequently reported adverse event with bremelanotide. In the RECONNECT trials, nausea occurred in 40.0% of patients in the bremelanotide arm compared with 1.3% in the placebo arm. Vomiting was reported in 4.7% of bremelanotide patients versus 0.4% placebo. These figures are drawn directly from the FDA summary basis of approval.

While nausea does not meet the threshold for "rare," its severity can escalate to a degree that requires medical evaluation. Prolonged vomiting leading to dehydration, electrolyte disturbances, or aspiration represents the serious end of this otherwise common adverse event spectrum.

Mitigation Strategies Supported by the Label

The prescribing label recommends that patients take an antiemetic approximately 1 hour before bremelanotide injection if they have experienced nausea on prior doses. Ondansetron 4 mg orally is the most commonly used option in clinical practice. Patients should also avoid dosing on an empty stomach, as co-administration with food did not meaningfully alter the pharmacokinetics of bremelanotide in Phase 1 studies. FDA clinical pharmacology review, available via accessdata.fda.gov, documents the food-effect analysis.

Injection Site Reactions and Local Adverse Events

Injection site reactions occurred in 13.2% of bremelanotide patients in the RECONNECT trials. Most were mild to moderate, consisting of bruising, erythema, and transient induration. No cases of injection site necrosis or abscess were reported in the key trial program. The full adverse event table appears in the FDA summary review.

Patients who inject into the same anatomical site repeatedly may develop subcutaneous lipohypertrophy, a recognized complication of repeated subcutaneous injections across drug classes. Rotating between the abdomen and thigh reduces this risk.

Flushing and Hot Flashes: Vasomotor Events

Flushing was reported in 20.3% of patients receiving bremelanotide in the RECONNECT program versus 2.5% of those receiving placebo. The mechanism is direct peripheral vasodilation through melanocortin receptor activation, the same mechanism that underlies the transient blood pressure changes discussed above. In most patients flushing is self-limited, peaking at 1 to 2 hours post-dose and resolving by hour 4. RECONNECT efficacy and safety data are summarized in the primary publication at PMID 31584796.

In patients with rosacea, carcinoid syndrome, or mastocytosis, the vasomotor response may be exaggerated and should be discussed before initiating therapy.

Drug Interactions With Clinical Significance

Naltrexone and Opioid Antagonist Interactions

The FDA label includes a specific drug interaction warning: bremelanotide may reduce the therapeutic effect of naltrexone and other opioid receptor antagonists. The mechanism is not fully established, but melanocortin and opioid receptor signaling pathways share downstream overlap in the hypothalamus. Patients on naltrexone for alcohol use disorder or opioid use disorder should not receive bremelanotide without a formal benefit-risk discussion. Section 7 of the prescribing label details this interaction.

Oral Medication Absorption

Because bremelanotide delays gastric emptying in some patients (a secondary MC4R effect similar to that seen with GLP-1 receptor agonists at lower magnitude), oral medications taken within 1 hour of injection may have altered absorption. This is particularly relevant for time-sensitive medications such as combined oral contraceptives, anticoagulants, and thyroid replacement therapy.

Special Populations: Elevated Risk Groups

Patients With Uncontrolled Hypertension

Blood pressure above 130/80 mmHg at the time of dosing should prompt delay of administration. The 2017 ACC/AHA hypertension guidelines reclassified stage 1 hypertension to begin at 130/80 mmHg. These guidelines are published in Hypertension (PMID 29133356). A patient whose baseline pressure sits at 128/78 and spikes 12 mmHg systemically after bremelanotide injection may cross into the range associated with end-organ risk if other vasopressors or stimulants are co-ingested on the same occasion.

Patients With Renal or Hepatic Impairment

Bremelanotide is cleared renally. In subjects with severe renal impairment (estimated GFR <30 mL/min/1.73 m²), area under the curve increased by approximately 63% compared with subjects with normal renal function. The pharmacokinetic data are documented in the FDA clinical pharmacology review. The label does not recommend a dose adjustment but does advise caution and increased monitoring frequency. For hepatic impairment, no clinically significant change in exposure was observed in mild-to-moderate hepatic impairment studies.

Pregnancy and Lactation

Bremelanotide is rated FDA Pregnancy Category N/A under current labeling conventions but carries a specific warning: animal reproductive studies showed fetal harm at exposures approximately 10 times the human area under the curve at 1.75 mg. FDA teratology data are summarized in section 8.1 of the prescribing label. Women who are or may become pregnant must not use this drug. No data exist on the presence of bremelanotide in human breast milk.

Post-Market Surveillance and FAERS: What Has Emerged

The post-approval field for bremelanotide has added several signal categories not prominently featured in the Phase 3 data. FAERS reports filed between the June 2019 approval date and the most recently released quarterly dataset include the following clinically actionable signals:

• Syncope or presyncope in the setting of the bremelanotide-associated hemodynamic shift, particularly in patients who stand abruptly within 2 hours of injection.
• Hypersensitivity reactions including urticaria and angioedema, reported at a frequency low enough to have been underrepresented in 1,267-patient Phase 3 trials.
• Reports of patients using bremelanotide more frequently than the labeled maximum of once per 24 hours, with cumulative pigmentation changes appearing earlier than the trial timeline predicted.

The FDA's 2024 drug safety communication archive should be checked regularly for any label updates. Access the FDA drug safety communications index at the FDA website.

The RECONNECT investigators noted in their 2019 publication that "the safety profile of bremelanotide was manageable, with most adverse events being transient and resolving without intervention," a characterization that remains accurate for the common adverse events but may underweight the seriousness of the rare cardiovascular and pigmentation signals identified post-market. PMID 31584796.

How to Counsel Patients Before the First Dose

Pre-Prescription Checklist

Every patient starting bremelanotide should receive structured counseling covering the following points, documented in the clinical note:

1. Blood pressure measured and confirmed below 130/80 mmHg on the day of the first prescription.
2. Cardiovascular history reviewed for any prior myocardial infarction, stroke, angina, or arrhythmia. Presence of any of these represents a hard contraindication.
3. Current medication list reviewed for naltrexone and time-sensitive oral drugs.
4. Skin and gum pigmentation documented at baseline, with photographs if available.
5. Pregnancy status confirmed negative, with reliable contraception in place.
6. Patient instructed to inject no more than once per 24 hours, and to sit or lie down for at least 2 hours after injection if she has experienced dizziness with prior doses.

What to Tell Patients About Self-Monitoring

Patients should know to take their blood pressure at home 1 to 2 hours after the first two doses and report any reading above 150/100 mmHg. They should examine their gums and face monthly under consistent lighting. Any new dark patches, especially on mucosal surfaces, should prompt a follow-up visit rather than an assumption of harmlessness.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that "treatment decisions should incorporate patient preferences, comorbidities, and the likelihood of adherence to monitoring requirements." This guideline is available via the Journal of Clinical Endocrinology and Metabolism (PMID 31513191).

Discontinuation Criteria and When to Stop

Stopping bremelanotide is warranted in the following scenarios, based on the prescribing label and post-market clinical guidance:

• Systolic blood pressure exceeding 160 mmHg or diastolic exceeding 100 mmHg confirmed on two measurements taken 5 minutes apart after dosing.
• Any new focal hyperpigmentation on the face, gums, or breast tissue, regardless of cosmetic impact to the patient.
• Any cardiovascular symptom including chest pain, palpitations lasting more than 10 minutes, syncope, or severe headache within 12 hours of injection.
• Confirmed pregnancy.
• Initiation of naltrexone or any scheduled opioid receptor antagonist.

Abrupt discontinuation carries no withdrawal risk. The drug's half-life is approximately 2.7 hours, meaning systemic exposure clears within 24 hours of the last dose. Pharmacokinetic data, including half-life, appear in the FDA clinical pharmacology review.